Insights

Here’s why the BARD1 (ASX:BD1) share price is frozen today

All eyes are on BARD1 Life Sciences’ halted shares.
The post Here’s why the BARD1 (ASX:BD1) share price is frozen today appeared first on The Motley Fool Australia. –

The BARD1 Life Sciences Ltd (ASX: BD1) share price is frozen today as the company prepares to announce news of a capital raise.

Trading of its shares will be halted until it either releases an announcement or the ASX opens on Friday morning.

The BARD1 Life Science share price finished yesterday’s session trading at $1.80.

The company is focused on creating non-invasive methods to detect early stage cancers.

Let’s take a closer look at today’s news of BARD1 Life Science.

Trading halt ahead of capital raise

The BARD1 Life Sciences share price is halted as it prepares to announce a $10 million placement and a $2 million share purchase plan. The share purchase plan is open to eligible retail investors.

The placement will see shares in BARD1 going for $1.55 apiece. That’s a 13.88% discount on its previous closing price.

The company is currently working on autoantibody tests that have been proven to detect some early-stage cancers.

Its lead pipeline product is its ovarian cancer tests. It is also working to create tests for early stage breast cancer.

Also in BARD1’s pipeline are tests for early stage lung cancer.

The BARD1 share price was temporarily boosted late last month by news its ovarian cancer detection technology had been published by international peer-reviewed journal Genes.

Today’s news is the first time the market has heard of a capital raise by BARD1 since June 2019.

Back then, the company raised $7.5 million to put towards its growth strategy.

BARD1 Life Sciences share price snapshot

2021 has been a good year so far for the BARD1 Life Sciences share price.

Right now, it’s 172% higher than it was at the start of the year. It has also gained 114% since this time last year.

The company has a market capitalisation of around $144 million, with approximately 80 million shares outstanding.

The post Here’s why the BARD1 (ASX:BD1) share price is frozen today appeared first on The Motley Fool Australia.

Should you invest $1,000 in BARD1 Life Sciences right now?

Before you consider BARD1 Life Sciences, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and BARD1 Life Sciences wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

Why the BARD1 (ASX:BD1) share price is surging 10% higher

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!